1
|
Wang T, Ma X, Ma C, Wu X, ZhaXi T, Yin L, Li W, Li Y, Liang C, Yan P. Whole genome resequencing-based analysis of plateau adaptation in Meiren yak ( Bos grunniens). Anim Biotechnol 2024; 35:2298406. [PMID: 38193808 DOI: 10.1080/10495398.2023.2298406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2024]
Abstract
The Meiren yak is an important genetic resource in Gansu Province, China. In this study, we aimed to explore the evolutionary history and population structure of the genetic resource of Meiren yak and to mine the characteristic genes of Meiren yak. We analysed a total of 93 yaks of eight yak breeds based on whole genome resequencing combined with population genomics and used θπ ratio and Fst method to screen the selected sites in the genome region. The results proved that Meiren yak can be used as a potential genetic resource in Gansu Province. The genes in Meiren yak with positive selection in selection signal analysis were subjected to the Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses, which indicated that the genes were related to the adaptability to high altitude and hypoxic environment. By analysing the genetic variation of Meiren yak at the genome-wide level, this study provided a theoretical basis for genetic improvement of Meiren yak and for the development of high-quality yak resources.
Collapse
Affiliation(s)
- Tong Wang
- Key Laboratory of Yak Breeding Engineering Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, China
- Key Laboratory of Animal Genetics and Breeding on Tibetan Plateau, Ministry of Agriculture and Rural Affairs, Lanzhou, China
- Life science and Engineering College, Northwest Minzu University, Lanzhou, China
| | - XiaoMing Ma
- Key Laboratory of Yak Breeding Engineering Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, China
- Key Laboratory of Animal Genetics and Breeding on Tibetan Plateau, Ministry of Agriculture and Rural Affairs, Lanzhou, China
| | - ChaoFan Ma
- Key Laboratory of Yak Breeding Engineering Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, China
- Key Laboratory of Animal Genetics and Breeding on Tibetan Plateau, Ministry of Agriculture and Rural Affairs, Lanzhou, China
- Life science and Engineering College, Northwest Minzu University, Lanzhou, China
| | - XiaoYun Wu
- Key Laboratory of Yak Breeding Engineering Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, China
- Key Laboratory of Animal Genetics and Breeding on Tibetan Plateau, Ministry of Agriculture and Rural Affairs, Lanzhou, China
| | - Ta ZhaXi
- Qilian County Veterinary Animal Husbandry Station, Qinghai, China
| | - LiXin Yin
- Huazhi Biotech Co. Ltd, Changsha, China
| | - WeiGuo Li
- Huazhi Biotech Co. Ltd, Changsha, China
| | - YuFei Li
- Huazhi Biotech Co. Ltd, Changsha, China
| | - ChunNian Liang
- Key Laboratory of Yak Breeding Engineering Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, China
- Key Laboratory of Animal Genetics and Breeding on Tibetan Plateau, Ministry of Agriculture and Rural Affairs, Lanzhou, China
| | - Ping Yan
- Key Laboratory of Yak Breeding Engineering Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, China
- Key Laboratory of Animal Genetics and Breeding on Tibetan Plateau, Ministry of Agriculture and Rural Affairs, Lanzhou, China
| |
Collapse
|
2
|
Probst-Hensch N, Bochud M, Chiolero A, Crivelli L, Dratva J, Flahault A, Frey D, Kuenzli N, Puhan M, Suggs LS, Wirth C. Swiss Cohort & Biobank - The White Paper. Public Health Rev 2022; 43:1605660. [PMID: 36619237 PMCID: PMC9817110 DOI: 10.3389/phrs.2022.1605660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 12/05/2022] [Indexed: 12/24/2022] Open
Affiliation(s)
- Nicole Probst-Hensch
- Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute (Swiss TPH), Allschwil, Switzerland
- University of Basel, Basel, Switzerland
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Swiss Society for Public Health, Bern, Switzerland
- *Correspondence: Nicole Probst-Hensch,
| | - Murielle Bochud
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Swiss Society for Public Health, Bern, Switzerland
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (Unisanté), Lausanne, Switzerland
| | - Arnaud Chiolero
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Swiss Society for Public Health, Bern, Switzerland
- Population Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, Switzerland
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
| | - Luca Crivelli
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Swiss Society for Public Health, Bern, Switzerland
- Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland
- Institute of Public Health Università della Svizzera Italiana, Lugano, Switzerland
| | - Julia Dratva
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Swiss Society for Public Health, Bern, Switzerland
- Institute of Public Health, Department of Health Sciences, ZHAW Zürich University of Applied Sciences, Winterthur, Switzerland
| | - Antoine Flahault
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Swiss Society for Public Health, Bern, Switzerland
- Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Daniel Frey
- Swiss Society for Public Health, Bern, Switzerland
| | - Nino Kuenzli
- Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute (Swiss TPH), Allschwil, Switzerland
- University of Basel, Basel, Switzerland
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Swiss Society for Public Health, Bern, Switzerland
| | - Milo Puhan
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland
| | - L. Suzanne Suggs
- Swiss School of Public Health (SSPH+), Zürich, Switzerland
- Swiss Society for Public Health, Bern, Switzerland
- Institute of Public Health Università della Svizzera Italiana, Lugano, Switzerland
| | - Corina Wirth
- Swiss Society for Public Health, Bern, Switzerland
| |
Collapse
|
3
|
The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families. Cancers (Basel) 2021; 13:cancers13143406. [PMID: 34298626 PMCID: PMC8305212 DOI: 10.3390/cancers13143406] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 06/23/2021] [Accepted: 06/24/2021] [Indexed: 12/19/2022] Open
Abstract
The French Canadian population of the province of Quebec has been recognized for its contribution to research in medical genetics, especially in defining the role of heritable pathogenic variants in cancer predisposing genes. Multiple carriers of a limited number of pathogenic variants in BRCA1 and BRCA2, the major risk genes for hereditary breast and/or ovarian cancer syndrome families, have been identified in French Canadians, which is in stark contrast to the array of over 2000 different pathogenic variants reported in each of these genes in other populations. As not all such cancer syndrome families are explained by BRCA1 and BRCA2, newly proposed gene candidates identified in other populations have been investigated for their role in conferring risk in French Canadian cancer families. For example, multiple carriers of distinct variants were identified in PALB2 and RAD51D. The unique genetic architecture of French Canadians has been attributed to shared ancestry due to common ancestors of early settlers of this population with origins mainly from France. In this review, we discuss the merits of genetically characterizing cancer predisposing genes in French Canadians of Quebec. We focused on genes that have been implicated in hereditary breast and/or ovarian cancer syndrome families as they have been the most thoroughly characterized cancer syndromes in this population. We describe how genetic analyses of French Canadians have facilitated: (i) the classification of variants in BRCA1 and BRCA2; (ii) the identification and classification of variants in newly proposed breast and/or ovarian cancer predisposing genes; and (iii) the identification of a new breast cancer predisposing gene candidate, RECQL. The genetic architecture of French Canadians provides a unique opportunity to evaluate new candidate cancer predisposing genes regardless of the population in which they were identified.
Collapse
|
4
|
Yang W, Gadgil P, Krishnamurthy VR, Landis M, Mallick P, Patel D, Patel PJ, Reid DL, Sanchez-Felix M. The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules. AAPS JOURNAL 2020; 22:21. [DOI: 10.1208/s12248-019-0402-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Accepted: 11/26/2019] [Indexed: 12/17/2022]
|
5
|
Abstract
More than a decade ago, the term "next-generation" sequencing was coined to describe what was, at the time, revolutionary new methods to sequence RNA and DNA at a faster pace and cheaper cost than could be performed by standard bench-top protocols. Since then, the field of DNA sequencing has evolved at a rapid pace, with new breakthroughs allowing capacity to exponentially increase and cost to dramatically decrease. As genome-scale sequencing has become routine, a paradigm shift is occurring in genomics, which uses the power of high-throughput, rapid sequencing power with large-scale studies. These new approaches to genetic discovery will provide direct impact to fields such as personalized medicine, evolution, and biodiversity. This work reviews recent technology advances and methods in next-generation sequencing and highlights current large-scale sequencing efforts driving the evolution of the genomics space.
Collapse
Affiliation(s)
- Shawn E Levy
- HudsonAlpha Institute for Biotechnology, Huntsville, Alabama 35806
| | - Braden E Boone
- HudsonAlpha Institute for Biotechnology, Huntsville, Alabama 35806
| |
Collapse
|
6
|
Roden DM. Phenome-wide association studies: a new method for functional genomics in humans. J Physiol 2017; 595:4109-4115. [PMID: 28229460 PMCID: PMC5471509 DOI: 10.1113/jp273122] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 02/01/2017] [Indexed: 01/08/2023] Open
Abstract
In experimental physiological research, a common study design for examining the functional role of a gene or a genetic variant is to introduce that genetic variant into a model organism (such as yeast or mouse) and then to search for phenotypic consequences. The development of DNA biobanks linked to dense phenotypic information enables such an experiment to be applied to human subjects in the form of a phenome-wide association study (PheWAS). The PheWAS paradigm takes advantage of a curated medical phenome, often derived from electronic health records, to search for associations between 'input functions' and phenotypes in an unbiased fashion. The most commonly studied input function to date has been single nucleotide polymorphisms (SNPs), but other inputs, such as sets of SNPs or a disease or drug exposure, are now being explored to probe the genetic and phenotypic architecture of human traits. Potential outcomes of these approaches include defining subsets of complex diseases (that can then be targeted by specific therapies) and drug repurposing.
Collapse
Affiliation(s)
- Dan M. Roden
- Departments of Medicine, Pharmacology and Biomedical InformaticsVanderbilt University Medical CenterNashvilleTNUSA
| |
Collapse
|
7
|
Roden DM. Reprint of Editiorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. Trends Cardiovasc Med 2017; 27:360-362. [PMID: 28601251 DOI: 10.1016/j.tcm.2017.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Dan M Roden
- Departments of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical Center, 2215B Garland Ave, 1285 MRBIV, Nashville, TN 37232-0575.
| |
Collapse
|
8
|
Roden DM. Editiorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. Trends Cardiovasc Med 2016; 27:203-206. [PMID: 27771237 DOI: 10.1016/j.tcm.2016.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2016] [Accepted: 09/10/2016] [Indexed: 11/28/2022]
Affiliation(s)
- Dan M Roden
- Departments of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical Center, 2215B Garland Ave, 1285 MRBIV, Nashville, TN 37232-0575.
| |
Collapse
|
9
|
Affiliation(s)
- Shawn E. Levy
- HudsonAlpha Institute for Biotechnology, Huntsville, Alabama 35806; ,
| | - Richard M. Myers
- HudsonAlpha Institute for Biotechnology, Huntsville, Alabama 35806; ,
| |
Collapse
|
10
|
Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol 2016; 12:335-43. [PMID: 27098907 DOI: 10.1038/nrrheum.2016.52] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Family history of rheumatoid arthritis (RA) is a proxy for an individual's genetic and, in part, environmental risk of developing RA, and is a well-recognized predictor of disease onset. Although family history of RA is an old concept, the degree of familial aggregation of RA, whether it differs by age, sex, or serology, and what value it has for clinical decisions once a diagnosis of RA has been made remain unclear. New data have been emerging in parallel to substantial progress made in genetic association studies. In this Review, we describe the various ways that familial aggregation has been measured, and how the findings from these studies, whether they are based on twins, cohorts of first-degree relatives, or genetic data, correspond to each other and aid understanding of the aetiology of RA. In addition, we review the potential usefulness of family history of RA from a clinical point of view, demonstrating that, in the era of big data and genomics, family history still has a role in directing clinical decision-making and research.
Collapse
Affiliation(s)
- Thomas Frisell
- Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, T2 Karolinska University Hospital, SE-171 76 Stockholm, Sweden
| | - Saedis Saevarsdottir
- Institute of Environmental Medicine, Karolinska Institutet, BOX 210, SE-171 77 Stockholm, Sweden.,Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
| | - Johan Askling
- Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, T2 Karolinska University Hospital, SE-171 76 Stockholm, Sweden.,Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
| |
Collapse
|
11
|
Peter J, Schacherer J. Population genomics of yeasts: towards a comprehensive view across a broad evolutionary scale. Yeast 2016; 33:73-81. [PMID: 26592376 DOI: 10.1002/yea.3142] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Revised: 10/30/2015] [Accepted: 11/02/2015] [Indexed: 11/08/2022] Open
Abstract
With the advent of high-throughput technologies for sequencing, the complete description of the genetic variation that occurs in populations, also known as population genomics, is foreseeable but far from being reached. Explaining the forces that govern patterns of genetic variation is essential to elucidate the evolutionary history of species. Genetic variation results from a wide assortment of evolutionary forces, among which mutation, selection, recombination and drift play major roles in shaping genomes. In addition, exploring the genetic variation within a population also corresponds to the first step towards dissecting the genotype-phenotype relationship. In this context, yeast species are of particular interest because they represent a unique resource for studying the evolution of intraspecific genetic diversity in a phylum spanning a broad evolutionary scale. Here, we briefly review recent progress in yeast population genomics and provide some perspective on this rapidly evolving field. In fact, we truly believe that it is of interest to supplement comparative and early population genomic studies with the deep sequencing of more extensive sets of individuals from the same species. In parallel, it would be more than valuable to uncover the intraspecific variation of a large number of unexplored species, including those that are closely and more distantly related. Altogether, these data would enable substantially more powerful genomic scans for functional dissection.
Collapse
Affiliation(s)
- Jackson Peter
- Department of Genetics, Genomics and Microbiology, University of Strasbourg/CNRS, UMR7156, Strasbourg, France
| | - Joseph Schacherer
- Department of Genetics, Genomics and Microbiology, University of Strasbourg/CNRS, UMR7156, Strasbourg, France
| |
Collapse
|
12
|
|
13
|
Olson JE, Ryu E, Johnson KJ, Koenig BA, Maschke KJ, Morrisette JA, Liebow M, Takahashi PY, Fredericksen ZS, Sharma RG, Anderson KS, Hathcock MA, Carnahan JA, Pathak J, Lindor NM, Beebe TJ, Thibodeau SN, Cerhan JR. The Mayo Clinic Biobank: a building block for individualized medicine. Mayo Clin Proc 2013; 88:952-62. [PMID: 24001487 PMCID: PMC4258707 DOI: 10.1016/j.mayocp.2013.06.006] [Citation(s) in RCA: 157] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2013] [Revised: 05/29/2013] [Accepted: 06/03/2013] [Indexed: 01/22/2023]
Abstract
OBJECTIVE To report the design and implementation of the first 3 years of enrollment of the Mayo Clinic Biobank. PATIENTS AND METHODS Preparations for this biobank began with a 4-day Deliberative Community Engagement with local residents to obtain community input into the design and governance of the biobank. Recruitment, which began in April 2009, is ongoing, with a target goal of 50,000. Any Mayo Clinic patient who is 18 years or older, able to consent, and a US resident is eligible to participate. Each participant completes a health history questionnaire, provides a blood sample, and allows access to existing tissue specimens and all data from their Mayo Clinic electronic medical record. A community advisory board provides ongoing advice and guidance on complex decisions. RESULTS After 3 years of recruitment, 21,736 individuals have enrolled. Fifty-eight percent (12,498) of participants are female and 95% (20,541) of European ancestry. Median participant age is 62 years. Seventy-four percent (16,171) live in Minnesota, with 42% (9157) from Olmsted County, where the Mayo Clinic in Rochester, Minnesota, is located. The 5 most commonly self-reported conditions are hyperlipidemia (8979, 41%), hypertension (8174, 38%), osteoarthritis (6448, 30%), any cancer (6224, 29%), and gastroesophageal reflux disease (5669, 26%). Among patients with self-reported cancer, the 5 most common types are nonmelanoma skin cancer (2950, 14%), prostate cancer (1107, 12% in men), breast cancer (941, 4%), melanoma (692, 3%), and cervical cancer (240, 2% in women). Fifty-six percent (12,115) of participants have at least 15 years of electronic medical record history. To date, more than 60 projects and more than 69,000 samples have been approved for use. CONCLUSION The Mayo Clinic Biobank has quickly been established as a valuable resource for researchers.
Collapse
Affiliation(s)
- Janet E Olson
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Gullapalli RR, Lyons-Weiler M, Petrosko P, Dhir R, Becich MJ, LaFramboise WA. Clinical integration of next-generation sequencing technology. Clin Lab Med 2013; 32:585-99. [PMID: 23078661 DOI: 10.1016/j.cll.2012.07.005] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Recent advances in next-generation sequencing (NGS) methods and technology have substantially reduced costs and operational complexity leading to production of benchtop sequencers and commercial software solutions for implementation in small research and clinical laboratories. This article addresses requirements and limitations to successful implementation of these systems, including (1) calibration and validation of the instrumentation, experimental paradigm, and primary readout, (2) secure data transfer, storage, and secondary processing, (3) implementation of software tools for targeted analysis, and (4) training of research and clinical personnel to evaluate data fidelity and interpret the molecular significance of the genomic output.
Collapse
Affiliation(s)
- R R Gullapalli
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
| | | | | | | | | | | |
Collapse
|
15
|
Lind L, Elmståhl S, Bergman E, Englund M, Lindberg E, Michaelsson K, Nilsson PM, Sundström J. EpiHealth: a large population-based cohort study for investigation of gene-lifestyle interactions in the pathogenesis of common diseases. Eur J Epidemiol 2013; 28:189-97. [PMID: 23435790 DOI: 10.1007/s10654-013-9787-x] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2012] [Accepted: 02/16/2013] [Indexed: 12/25/2022]
Abstract
The most common diseases affecting middle-aged and elderly subjects in industrialized countries are multigenetic and lifestyle related. Several attempts have been made to study interactions between genes and lifestyle factors, but most such studies lack the power to examine interactions between several genes and several lifestyle components. The primary objective of the EpiHealth cohort study is to provide a resource to study interactions between several genotypes and lifestyle factors in a large cohort (the aim is 300,000 individuals) derived from the Swedish population in the age range of 45-75 years regarding development of common degenerative disorders, such as cardiovascular diseases, cancer, dementia, joint pain, obstructive lung disease, depression, and osteoporotic fractures. The study consists of three parts. First, a collection of data on lifestyle factors by self-assessment using an internet-based questionnaire. Second, a visit to a test center where blood samples are collected and physiological parameters recorded. Third, the sample is followed for occurrence of outcomes using nationwide medical registers. This overview presents the study design and some baseline characteristics from the first year of data collection in the EpiHealth study.
Collapse
Affiliation(s)
- Lars Lind
- Department of Medical Sciences, Uppsala University, 751 85, Uppsala, Sweden.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Whitfield JB. Genetics and molecular biology in laboratory medicine, 1963-2013. Clin Chem Lab Med 2012; 51:113-7. [PMID: 23095204 DOI: 10.1515/cclm-2012-0478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2012] [Accepted: 07/30/2012] [Indexed: 11/15/2022]
Abstract
The past 50 years have seen many changes in laboratory medicine, either as causes or consequences of increases in productivity and expansion of the range of information which can be provided. The drivers and facilitators of change in relation to clinical applications of molecular biology included the need for diagnostic tools for genetic diseases and technical advances such as PCR and sequencing. However, molecular biology techniques have proved to have far wider applications, from detection of infectious agents to molecular characterization of tumors. Journals such as Clinical Chemistry and Laboratory Medicine play an important role in communication of these advances to the laboratory medicine community and in publishing evaluations of their practical value.
Collapse
Affiliation(s)
- John B Whitfield
- Genetic Epidemiology, Queensland Institute of Medical Research, Brisbane, Australia.
| |
Collapse
|
17
|
Computer-based genealogy reconstruction in founder populations. J Biomed Inform 2011; 44:997-1003. [PMID: 21884821 DOI: 10.1016/j.jbi.2011.08.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2010] [Revised: 06/21/2011] [Accepted: 08/04/2011] [Indexed: 11/22/2022]
Abstract
This paper describes a software tool that reconstructs entire genealogies from data collected from different and heterogeneous sources, including municipal and parish records archived over centuries. The tool exploits a record linkage algorithm relying on a rule-based data matching approach. It applies a general strategy for managing the ambiguities due to missing, imprecise or erroneous input data. The process follows an iterative approach that combines automatic pedigree reconstruction with software-empowered human data revision to improve the quality and the accuracy of the results and to optimize the matching rules. The paper discusses the results obtained by reconstructing the entire genealogy of the population of the Val Borbera, a geographically isolated valley in Northern Italy. The genealogy could be reconstructed from data going back as far as the XVI century. The resulting pedigree includes 75,994 trios, 58.9% of which belonging to a unique big family, reconstructed over 13 generations.
Collapse
|
18
|
|
19
|
Almqvist C, Adami HO, Franks PW, Groop L, Ingelsson E, Kere J, Lissner L, Litton JE, Maeurer M, Michaëlsson K, Palmgren J, Pershagen G, Ploner A, Sullivan PF, Tybring G, Pedersen NL. LifeGene--a large prospective population-based study of global relevance. Eur J Epidemiol 2011; 26:67-77. [PMID: 21104112 PMCID: PMC7087900 DOI: 10.1007/s10654-010-9521-x] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2010] [Accepted: 11/02/2010] [Indexed: 11/04/2022]
Abstract
Studying gene-environment interactions requires that the amount and quality of the lifestyle data is comparable to what is available for the corresponding genomic data. Sweden has several crucial prerequisites for comprehensive longitudinal biomedical research, such as the personal identity number, the universally available national health care system, continuously updated population and health registries and a scientifically motivated population. LifeGene builds on these strengths to bridge the gap between basic research and clinical applications with particular attention to populations, through a unique design in a research-friendly setting. LifeGene is designed both as a prospective cohort study and an infrastructure with repeated contacts of study participants approximately every 5 years. Index persons aged 18-45 years old will be recruited and invited to include their household members (partner and any children). A comprehensive questionnaire addressing cutting-edge research questions will be administered through the web with short follow-ups annually. Biosamples and physical measurements will also be collected at baseline, and re-administered every 5 years thereafter. Event-based sampling will be a key feature of LifeGene. The household-based design will give the opportunity to involve young couples prior to and during pregnancy, allowing for the first study of children born into cohort with complete pre-and perinatal data from both the mother and father. Questions and sampling schemes will be tailored to the participants' age and life events. The target of LifeGene is to enroll 500,000 Swedes and follow them longitudinally for at least 20 years.
Collapse
Affiliation(s)
- Catarina Almqvist
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE-171 77 Stockholm, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
Genome-wide association studies (GWAS) provide an important avenue for undertaking an agnostic evaluation of the association between common genetic variants and risk of disease. Recent advances in our understanding of human genetic variation and the technology to measure such variation have made GWAS feasible. Over the past few years a multitude of GWAS have identified and replicated many associated variants. These findings are enriching our knowledge about the genetic basis of disease and leading some to advocate using GWA study results for genetic testing. For many of the GWA study results, however, the underlying mechanisms remain unclear and the findings explain only a limited amount of heritability. These issues may be clarified by more detailed investigations, including analyses of less common variants, sequence-level data, and environmental exposures. Such studies should help clarify the potential value of genetic testing to the public's health.
Collapse
Affiliation(s)
- John S Witte
- Institute for Human Genetics, Departments of Epidemiology and Biostatistics and Urology, University of California, San Francisco, San Francisco, California 94158-9001, USA.
| |
Collapse
|
21
|
Abstract
Pituitary tumors are prevalent in the general population, with a frequency of nearly 1 in 5. The cause of most pituitary tumors remains unknown, although a genetic contribution is recognized for some. We analyzed the Utah Population Data Base (UPDB), a resource combining a computerized genealogy of the Utah population with a statewide tumor registry, to investigate familial clustering of pituitary tumors. We analyzed the genetic relationships among 741 individuals diagnosed with benign or malignant pituitary tumors who had Utah genealogy data. To test for evidence of genetic contribution to predisposition, we compared average relatedness between all pairs of individuals with pituitary tumors with the expected relatedness in this population. We also estimated relative risks (RRs) for pituitary tumors in close and distant relatives of cases by comparing observed and expected numbers of cases among relatives. Relative risks for first- and third-degree relatives were significantly elevated (RR = 2.83 and 1.63, respectively), while relative risk for second-degree relatives was not significantly different from 1.0 (RR = 0.83). The average pairwise relatedness of pituitary tumor cases was significantly higher than expected, even when close relationships were ignored. The significantly elevated risks to relatives as well as the significant excess distant relatedness observed in cases provide strong support for a genetic contribution to predisposition to pituitary tumors. Multiple high-risk pedigrees can be identified in the UPDB, and study of such pedigrees might allow identification of the gene(s) responsible for our observations. Recognizing genetic contribution to the disease may also help with counseling family members of affected individuals.
Collapse
Affiliation(s)
- William T Couldwell
- Department of Neurosurgery, University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
| | | |
Collapse
|
22
|
Abstract
PURPOSE Large cohort studies to investigate interactions between genes, environment, and lifestyle require large representative samples of the population. The Department of Veterans Affairs health care system is uniquely positioned to carry out such research, with a large patient population and a sophisticated system of electronic medical records. As Veterans Affairs considers establishing a large database of genetic information and medical records for research purposes, a survey of 931 Veterans Affairs patients was carried out to measure their willingness to participate, what their concerns would be, and their preferences about some aspects of study design. METHODS A sample of veterans who receive Veterans Affairs health care was surveyed online in April and May of 2008. The proposed genomic study was described to respondents, who then were asked about their support for the study and willingness to participate, and their opinions about the study and some of its components. A descriptive analysis examined differences in attitudes among demographic groups, and whether general beliefs were associated with support or willingness to participate. RESULTS Most respondents (83%) said the database should definitely or probably be created, and overall, 71% said they would definitely or probably participate. CONCLUSION Majorities of Veterans Affairs health patients in a broad range of demographic groups supported the establishment of a genomic database and showed willingness to participate. Although the desire to learn about one's own health from the study was high, altruistic characteristics were strongly related to whether or not veterans would participate.
Collapse
|
23
|
Abstract
PURPOSE Cohort studies investigating genes, environment, and lifestyle require large study populations. To recruit and retain participants, it is important to understand the relative significance of influences on people's motivation to participate. To this end, 4659 Americans were surveyed about support for and willingness to participate in a proposed large cohort study. METHODS An online survey of US adults was conducted between December 2007 and January 2008. To measure the influence of study burden, compensation and receipt of individual research results on willingness to participate, respondents were randomized to one of eight different study scenarios. RESULTS Most respondents (84%) supported the study, and 60% would participate. Returning research results (odds ratio = 1.6, 95% confidence interval 1.3-1.8) and increasing compensation from $50 to $200 (odds ratio = 1.5, 95% confidence interval 1.2-1.7) were associated with increased willingness to participate. Decreasing study burden was less important (odds ratio = 1.2, 95% confidence interval 1.0-1.4). Three in four respondents would be less likely to participate without the return of research results. Support and willingness varied little among demographic groups; variation in influences of the three factors on willingness was observed. CONCLUSION Widespread support exists in the general public for a large national cohort study. Providing individual research results is a strong motivation to participate; compensating participants $200 may increase participation a similar amount. Incentives, recruitment, and return of results could be tailored to demographics groups' interests.
Collapse
|
24
|
Bellis C, Cox HC, Dyer TD, Charlesworth JC, Begley KN, Quinlan S, Lea RA, Heath SC, Blangero J, Griffiths LR. Linkage mapping of CVD risk traits in the isolated Norfolk Island population. Hum Genet 2008; 124:543-52. [PMID: 18975005 DOI: 10.1007/s00439-008-0580-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2008] [Accepted: 10/21/2008] [Indexed: 01/04/2023]
Abstract
To understand the underlying genetic architecture of cardiovascular disease (CVD) risk traits, we undertook a genome-wide linkage scan to identify CVD quantitative trait loci (QTLs) in 377 individuals from the Norfolk Island population. The central aim of this research focused on the utilization of a genetically and geographically isolated population of individuals from Norfolk Island for the purposes of variance component linkage analysis to identify QTLs involved in CVD risk traits. Substantial evidence supports the involvement of traits such as systolic and diastolic blood pressures, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, body mass index and triglycerides as important risk factors for CVD pathogenesis. In addition to the environmental influences of poor diet, reduced physical activity, increasing age, cigarette smoking and alcohol consumption, many studies have illustrated a strong involvement of genetic components in the CVD phenotype through family and twin studies. We undertook a genome scan using 400 markers spaced approximately 10 cM in 600 individuals from Norfolk Island. Genotype data was analyzed using the variance components methods of SOLAR. Our results gave a peak LOD score of 2.01 localizing to chromosome 1p36 for systolic blood pressure and replicated previously implicated loci for other CVD relevant QTLs.
Collapse
Affiliation(s)
- C Bellis
- Genomics Research Centre, Griffith Institute for Health and Medical Research, Griffith University, Gold Coast PMB 50, GCMC Bundall 9726, Gold Coast, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008; 84:362-9. [PMID: 18500243 DOI: 10.1038/clpt.2008.89] [Citation(s) in RCA: 693] [Impact Index Per Article: 43.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Our objective was to develop a DNA biobank linked to phenotypic data derived from an electronic medical record (EMR) system. An "opt-out" model was implemented after significant review and revision. The plan included (i) development and maintenance of a de-identified mirror image of the EMR, namely, the "synthetic derivative" (SD) and (ii) DNA extracted from discarded blood samples and linked to the SD. Surveys of patients indicated general acceptance of the concept, with only a minority ( approximately 5%) opposing it. As a result, mechanisms to facilitate opt-out included publicity and revision of a standard "consent to treatment" form. Algorithms for sample handling and procedures for de-identification were developed and validated in order to ensure acceptable error rates (<0.3 and <0.1%, respectively). The rate of sample accrual is 700-900 samples/week. The advantages of this approach are the rate of sample acquisition and the diversity of phenotypes based on EMRs.
Collapse
|
26
|
Bellis C, Cox HC, Ovcaric M, Begley KN, Lea RA, Quinlan S, Burgner D, Heath SC, Blangero J, Griffiths LR. Linkage disequilibrium analysis in the genetically isolated Norfolk Island population. Heredity (Edinb) 2007; 100:366-73. [PMID: 18091769 DOI: 10.1038/sj.hdy.6801083] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Norfolk Island is a human genetic isolate, possessing unique population characteristics that could be utilized for complex disease gene localization. Our intention was to evaluate the extent and strength of linkage disequilibrium (LD) in the Norfolk isolate by investigating markers within Xq13.3 and the NOS2A gene encoding the inducible nitric oxide synthase. A total of six microsatellite markers spanning approximately 11 Mb were assessed on chromosome Xq13.3 in a group of 56 men from Norfolk Island. Additionally, three single nucleotide polymorphisms (SNPs) localizing to the NOS2A gene were analyzed in a subset of the complex Norfolk pedigree. With the exception of two of the marker pairs, one of which is the most distantly spaced marker, all the Xq13.3 marker pairs were found to be in significant LD indicating that LD extends up to 9.5-11.5 Mb in the Norfolk Island population. Also, all SNPs studied showed significant LD in both Norfolk Islanders and Australian Caucasians, with two of the marker pairs in complete LD in the Norfolk population only. The Norfolk Island study population possesses a unique set of characteristics including founder effect, geographical isolation, exhaustive genealogical information and phenotypic data of use to cardiovascular disease risk traits. With LD extending up to 9.5-11 Mb, the Norfolk isolate should be a powerful resource for the localization of complex disease genes.
Collapse
Affiliation(s)
- C Bellis
- Genomics Research Centre, School of Medical Science, Griffith University, Gold Coast, Bundall, Australia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Teerlink CC, Hegewald MJ, Cannon-Albright LA. A genealogical assessment of heritable predisposition to asthma mortality. Am J Respir Crit Care Med 2007; 176:865-70. [PMID: 17690335 DOI: 10.1164/rccm.200703-448oc] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
RATIONALE Asthma is a multifactorial disease; genetic factors have been suggested but have not been well defined. OBJECTIVES This study examined evidence for a heritable component to asthma mortality using a unique data resource consisting of Utah death certificates linked to a genealogy of Utah. METHODS Cases were defined as individuals whose death certificate listed asthma as a cause of death in a registry of all Utah deaths since 1904 (n = 1,553). The genealogical index of familiality analysis was used to compare the average relatedness of asthma deaths to the expected relatedness in the Utah population. Relative risks for asthma death in relatives of individuals who died of asthma are provided for close and distant relatives. MEASUREMENTS AND MAIN RESULTS The genealogical index of familiality identified a significantly higher average relatedness in cases (P < 0.001), even when close relationships were ignored. In addition, a significantly increased risk of dying of asthma was observed in first-degree relatives of cases (relative risk = 1.69, P < 0.001) and in second-degree relatives of cases (relative risk = 1.34, P = 0.003). CONCLUSIONS These results support a heritable contribution to asthma mortality.
Collapse
Affiliation(s)
- Craig C Teerlink
- Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah 84112-5750, USA.
| | | | | |
Collapse
|
28
|
Glasson EJ, de Klerk NH, Bass AJ, Rosman DL, Palmer LJ, Holman CDJ. Cohort Profile: The Western Australian Family Connections Genealogical Project. Int J Epidemiol 2007; 37:30-5. [PMID: 17611241 DOI: 10.1093/ije/dym136] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Affiliation(s)
- E J Glasson
- Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, Perth, Australia.
| | | | | | | | | | | |
Collapse
|
29
|
Hjartardottir S, Leifsson BG, Geirsson RT, Steinthorsdottir V. Recurrence of hypertensive disorder in second pregnancy. Am J Obstet Gynecol 2006; 194:916-20. [PMID: 16580276 DOI: 10.1016/j.ajog.2005.10.819] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2005] [Revised: 09/24/2005] [Accepted: 10/27/2005] [Indexed: 10/24/2022]
Abstract
OBJECTIVE The purpose of this study was to investigate the recurrence of hypertensive disorders in pregnancy with regard to the type of disorder, the onset of hypertension, and the modulating effect of overweight and weight gain between pregnancies. STUDY DESIGN Maternity records from 896 parous women with hypertensive disorders in pregnancy in the first pregnancy were reviewed to reclassify disease status and calculate odds ratios for recurrence. RESULTS Recurrence of hypertensive disorders in pregnancy occurred in 58% to 94% of second pregnancies, depending on first pregnancy disorder. Overweight (odds ratio, 1.82) and weight gain (odds ratio, 2.20) were related to recurrence among women with gestational hypertension. Early hypertension (<or =34 weeks of gestation) increased the recurrence risk for women with gestational hypertension (odds ratio, 1.85) and preeclampsia (odds ratio, 3.42). CONCLUSION Recurrence of hypertensive disorders in pregnancy is common, but not specified by type of disorder in first pregnancy. Overweight and weight gain between pregnancies are associated with recurrent hypertensive disorders in pregnancy in women with gestational hypertension. Early onset of hypertension is a risk factor, independent of body weight.
Collapse
Affiliation(s)
- Sigrun Hjartardottir
- Department of Obstetrics and Gynecology, Landspítali University Hospital, University of Iceland, Reykjavík, Iceland.
| | | | | | | |
Collapse
|
30
|
Bellis C, Hughes RM, Begley KN, Quinlan S, Lea RA, Heath SC, Blangero J, Griffiths LR. Phenotypical Characterisation of the Isolated Norfolk Island Population Focusing on Epidemiological Indicators of Cardiovascular Disease. Hum Hered 2006; 60:211-9. [PMID: 16391489 DOI: 10.1159/000090545] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2005] [Accepted: 08/11/2005] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVES Only 193 people from Pitcairn Island, all descended from 9 'Bounty' mutineers and 12 Tahitian women, moved to the uninhabited Norfolk Island in 1856. Our objective was to assess the population of Norfolk Island, several thousand km off the eastern coast of Australia, as a genetic isolate of potential use for cardiovascular disease (CVD) gene mapping. METHODS A total of 602 participants, approximately two thirds of the island's present adult population, were characterized for a panel of CVD risk factors. Statistical power and heritability were calculated. RESULTS Norfolk Islander's possess an increased prevalence of hypertension, obesity and multiple CVD risk factors when compared to outbred Caucasian populations. 64% of the study participants were descendents of the island's original founder population. Triglycerides, cholesterol, and blood pressures all had heritabilities above 0.2. CONCLUSIONS The Norfolk Island population is a potentially useful genetic isolate for gene mapping studies aimed at identifying CVD risk factor quantitative trait loci (QTL).
Collapse
Affiliation(s)
- Claire Bellis
- Genomics Research Centre, School of Medical Science, Griffith University, Gold Coast, Gold Coast Mail Centre Queensland, Australia
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Kalaydjieva L, Morar B, Chaix R, Tang H. A newly discovered founder population: the Roma/Gypsies. Bioessays 2005; 27:1084-94. [PMID: 16163730 DOI: 10.1002/bies.20287] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The Gypsies (a misnomer, derived from an early legend about Egyptian origins) defy the conventional definition of a population: they have no nation-state, speak different languages, belong to many religions and comprise a mosaic of socially and culturally divergent groups separated by strict rules of endogamy. Referred to as "the invisible minority", the Gypsies have for centuries been ignored by Western medicine, and their genetic heritage has only recently attracted attention. Common origins from a small group of ancestors characterise the 8-10 million European Gypsies as an unusual trans-national founder population, whose exodus from India played the role of a profound demographic bottleneck. Social and economic pressures within Europe led to gradual fragmentation, generating multiple genetically differentiated subisolates. The string of population bottlenecks and founder effects have shaped a unique genetic profile, whose potential for genetic research can be met only by study designs that acknowledge cultural tradition and self-identity.
Collapse
Affiliation(s)
- Luba Kalaydjieva
- Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, Australia.
| | | | | | | |
Collapse
|
32
|
Foster MW, Sharp RR. Will investments in biobanks, prospective cohorts, and markers of common patterns of variation benefit other populations for drug response and disease susceptibility gene discovery? THE PHARMACOGENOMICS JOURNAL 2005; 5:75-80. [PMID: 15668730 DOI: 10.1038/sj.tpj.6500295] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M W Foster
- Department of Anthropology, University of Oklahoma, Norman, OK 73019, USA.
| | | |
Collapse
|
33
|
Karason A, Gudjonsson JE, Jónsson HH, Hauksson VB, Runarsdottir EH, Stefansson K, Valdimarsson H, Gulcher JR. Genetics of Psoriasis in Iceland: Evidence for Linkage of Subphenotypes to Distinct Loci. J Invest Dermatol 2005; 124:1177-85. [PMID: 15955092 DOI: 10.1111/j.0022-202x.2005.23703.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Psoriasis is a chronic inflammatory skin disease with overlapping subphenotypes. It has a strong complex genetic component, but has been problematic to identifying significant loci. We evaluated 1000 patients with chronic plaque psoriasis and documented several subphenotypes. Here we report results of genome-wide linkage scans for psoriasis genes in 238 Icelandic families with 874 patients. MHC linkage was confirmed with LOD score of 10.9. When the entire cohort was analyzed, two other loci with LOD scores of 2.5 and 1.5 were observed on 16q and 4q, respectively. Stratification into subphenotypes revealed additional loci with LOD scores exceeding or approaching significance. A LOD score of 5.7 appeared on 16q in PsA patients with analysis conditioned on parental inheritance. A LOD score of 3.6 on 4q was detected when disease occurred at or older than 17 y, our median cohort age. This locus was defined by a marker near one reportedly displaying significant linkage in a Chinese psoriasis population and near suggestive linkage in a Caucasian population. A LOD of 3.0 was observed on 10q when disease onset occurred in the scalp. Furthermore, clinical stratification either revealed or increased LOD scores when compared to unstratified analysis and some coincided with previous reports.
Collapse
|
34
|
Abstract
In this article, the authors argue that the overwhelming portion of the literature on intelligence, race, and genetics is based on folk taxonomies rather than scientific analysis. They suggest that because theorists of intelligence disagree as to what it is, any consideration of its relationships to other constructs must be tentative at best. They further argue that race is a social construction with no scientific definition. Thus, studies of the relationship between race and other constructs may serve social ends but cannot serve scientific ends. No gene has yet been conclusively linked to intelligence, so attempts to provide a compelling genetic link of race to intelligence are not feasible at this time. The authors also show that heritability, a behavior-genetic concept, is inadequate in regard to providing such a link.
Collapse
|
35
|
Clarimon J, Asgeirsson H, Singleton A, Jakobsson F, Hjaltason H, Hardy J, Sveinbjornsdottir S. Torsin A haplotype predisposes to idiopathic dystonia. Ann Neurol 2005; 57:765-7. [PMID: 15852391 DOI: 10.1002/ana.20485] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Previous work has suggested that in many neurological diseases genetic variability in the loci predisposing subjects to autosomal dominant disease contributes to the risk of sporadic disease. Here, using a population-based sample of dystonia cases, we show an association with the torsin A haplotype and sporadic idiopathic dystonia.
Collapse
Affiliation(s)
- Jordi Clarimon
- Laboratory of Neurogenetics, Porter Building, Bethesda, MD, USA
| | | | | | | | | | | | | |
Collapse
|
36
|
Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, Gulcher JR, Bjornsson J, Kong A, Thorsteinsdottir U, Stefansson K. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004; 1:e65. [PMID: 15630470 PMCID: PMC539051 DOI: 10.1371/journal.pmed.0010065] [Citation(s) in RCA: 217] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2004] [Accepted: 10/27/2004] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND The contribution of low-penetrant susceptibility variants to cancer is not clear. With the aim of searching for genetic factors that contribute to cancer at one or more sites in the body, we have analyzed familial aggregation of cancer in extended families based on all cancer cases diagnosed in Iceland over almost half a century. METHODS AND FINDINGS We have estimated risk ratios (RRs) of cancer for first- and up to fifth-degree relatives both within and between all types of cancers diagnosed in Iceland from 1955 to 2002 by linking patient information from the Icelandic Cancer Registry to an extensive genealogical database, containing all living Icelanders and most of their ancestors since the settlement of Iceland. We evaluated the significance of the familial clustering for each relationship separately, all relationships combined (first- to fifth-degree relatives) and for close (first- and second-degree) and distant (third- to fifth-degree) relatives. Most cancer sites demonstrate a significantly increased RR for the same cancer, beyond the nuclear family. Significantly increased familial clustering between different cancer sites is also documented in both close and distant relatives. Some of these associations have been suggested previously but others not. CONCLUSION We conclude that genetic factors are involved in the etiology of many cancers and that these factors are in some cases shared by different cancer sites. However, a significantly increased RR conferred upon mates of patients with cancer at some sites indicates that shared environment or nonrandom mating for certain risk factors also play a role in the familial clustering of cancer. Our results indicate that cancer is a complex, often non-site-specific disease for which increased risk extends beyond the nuclear family.
Collapse
Affiliation(s)
- Laufey T Amundadottir
- 1deCODE GeneticsReykjavikIceland
- *To whom correspondence should be addressed. E-mail: (LTA), E-mail: (KS)
| | | | | | | | | | | | | | | | | | | | - Kari Stefansson
- 1deCODE GeneticsReykjavikIceland
- *To whom correspondence should be addressed. E-mail: (LTA), E-mail: (KS)
| |
Collapse
|
37
|
Morar B, Gresham D, Angelicheva D, Tournev I, Gooding R, Guergueltcheva V, Schmidt C, Abicht A, Lochmüller H, Tordai A, Kalmár L, Nagy M, Karcagi V, Jeanpierre M, Herczegfalvi A, Beeson D, Venkataraman V, Warwick Carter K, Reeve J, de Pablo R, Kučinskas V, Kalaydjieva L. Mutation history of the roma/gypsies. Am J Hum Genet 2004; 75:596-609. [PMID: 15322984 PMCID: PMC1182047 DOI: 10.1086/424759] [Citation(s) in RCA: 126] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2004] [Accepted: 07/20/2004] [Indexed: 11/03/2022] Open
Abstract
The 8-10 million European Roma/Gypsies are a founder population of common origins that has subsequently split into multiple socially divergent and geographically dispersed Gypsy groups. Unlike other founder populations, whose genealogy has been extensively documented, the demographic history of the Gypsies is not fully understood and, given the lack of written records, has to be inferred from current genetic data. In this study, we have used five disease loci harboring private Gypsy mutations to examine some missing historical parameters and current structure. We analyzed the frequency distribution of the five mutations in 832-1,363 unrelated controls, representing 14 Gypsy populations, and the diversification of chromosomal haplotypes in 501 members of affected families. Sharing of mutations and high carrier rates supported a strong founder effect, and the identity of the congenital myasthenia 1267delG mutation in Gypsy and Indian/Pakistani chromosomes provided the best evidence yet of the Indian origins of the Gypsies. However, dramatic differences in mutation frequencies and haplotype divergence and very limited haplotype sharing pointed to strong internal differentiation and characterized the Gypsies as a founder population comprising multiple subisolates. Using disease haplotype coalescence times at the different loci, we estimated that the entire Gypsy population was founded approximately 32-40 generations ago, with secondary and tertiary founder events occurring approximately 16-25 generations ago. The existence of multiple subisolates, with endogamy maintained to the present day, suggests a general approach to complex disorders in which initial gene mapping could be performed in large families from a single Gypsy group, whereas fine mapping would rely on the informed sampling of the divergent subisolates and searching for the shared genomic region that displays the strongest linkage disequilibrium with the disease.
Collapse
Affiliation(s)
- Bharti Morar
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - David Gresham
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Dora Angelicheva
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Ivailo Tournev
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Rebecca Gooding
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Velina Guergueltcheva
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Carolin Schmidt
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Angela Abicht
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Hanns Lochmüller
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Attila Tordai
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Lajos Kalmár
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Melinda Nagy
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Veronika Karcagi
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Marc Jeanpierre
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Agnes Herczegfalvi
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - David Beeson
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Viswanathan Venkataraman
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Kim Warwick Carter
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Jeff Reeve
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Rosario de Pablo
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Vaidutis Kučinskas
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Luba Kalaydjieva
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| |
Collapse
|
38
|
Abstract
A detailed analysis of the Icelandic commercial population-wide genomics database project of deCODE Genetics was performed for the purpose of providing ethics insights into public/private efforts to develop genetic databases. This analysis examines the moral differences between the general case of governmental collection of medical data for public health purposes and the centralized collection planned in Iceland. Both the process of developing the database and its design vary in significant ways from typical government data collection and analysis activities. Because of these differences, the database may serve the interests of deCODE more than it serves the interests of the public, undermining the claim that presumed consent for this data collection and its proprietary use is ethical. We believe that there is an evolving consensus that informed consent of participants must be secured for population-based genetics databases and research. The Iceland model provides an informative counterexample that holds key ethics lessons for similar ventures.
Collapse
Affiliation(s)
- Jon F Merz
- Center for Bioethics, University of Pennsylvania, Philadelphia, PA 19104-3308, USA.
| | | | | |
Collapse
|
39
|
Birkisson IF, Halapi E, Bjornsdottir US, Shkolny DL, Adalsteinsdottir E, Arnason T, Gislason D, Gislason T, Gulcher J, Stefansson K, Hakonarson H. Genetic approaches to assessing evidence for a T helper type 1 cytokine defect in adult asthma. Am J Respir Crit Care Med 2004; 169:1007-13. [PMID: 14962816 DOI: 10.1164/rccm.200302-228oc] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Recent evidence suggests that deficiency in the Th1 cytokine pathway may underlie the susceptibility to allergic asthma. This study examined whether (1) single-nucleotide polymorphisms exist in the promoter region of the two interleukin (IL)-12 subunit genes in patients with asthma; (2) messenger RNA and protein expressions of signal transducers and activators of transcription, IL-12, IFN-gamma, and their receptors are altered in asthma; and (3) linkage to genes in the Th1 pathway is present in families with asthma in Iceland. The promoter regions of the IL-12 subunit genes were sequenced in 94 patients with asthma and 94 control subjects without asthma. Linkage was examined in 169 families that included over 570 patients with asthma and 950 of their unaffected relatives. The results demonstrate no evidence of linkage to microsatellite markers in close association with genes within the Th1 pathway, and no polymorphism was detected in the promoter regions of the two IL-12 subunit genes in the cohort with asthma patients. Moreover, we found no differences in the messenger RNA or protein expression signals of genes in the IL-12 pathway between the patients and control subjects. We conclude that decrease in Th1 type cytokine response is unlikely to present a primary event in asthma.
Collapse
MESH Headings
- Adolescent
- Adult
- Asthma/epidemiology
- Asthma/genetics
- Asthma/immunology
- Case-Control Studies
- Child
- Enzyme-Linked Immunosorbent Assay
- Female
- Flow Cytometry
- Genetic Linkage/genetics
- Genetic Linkage/immunology
- Genotype
- Humans
- Hypersensitivity, Immediate/epidemiology
- Hypersensitivity, Immediate/genetics
- Hypersensitivity, Immediate/immunology
- Interferon-gamma/genetics
- Interferon-gamma/immunology
- Interleukin-12/genetics
- Interleukin-12/immunology
- Male
- Microsatellite Repeats/genetics
- Microsatellite Repeats/immunology
- Middle Aged
- Phenotype
- Polymerase Chain Reaction
- Polymorphism, Single Nucleotide/genetics
- Promoter Regions, Genetic/genetics
- Promoter Regions, Genetic/immunology
- RNA, Messenger/genetics
- RNA, Messenger/immunology
- Signal Transduction/genetics
- Signal Transduction/immunology
- Th1 Cells/immunology
- Transcription, Genetic/genetics
- Transcription, Genetic/immunology
Collapse
|
40
|
Luikart G, England PR, Tallmon D, Jordan S, Taberlet P. The power and promise of population genomics: from genotyping to genome typing. Nat Rev Genet 2003; 4:981-94. [PMID: 14631358 DOI: 10.1038/nrg1226] [Citation(s) in RCA: 742] [Impact Index Per Article: 35.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Population genomics has the potential to improve studies of evolutionary genetics, molecular ecology and conservation biology, by facilitating the identification of adaptive molecular variation and by improving the estimation of important parameters such as population size, migration rates and phylogenetic relationships. There has been much excitement in the recent literature about the identification of adaptive molecular variation using the population-genomic approach. However, the most useful contribution of the genomics model to population genetics will be improving inferences about population demography and evolutionary history.
Collapse
Affiliation(s)
- Gordon Luikart
- Laboratoire d'Ecologie Alpine, Génomique des Populations et Biodiversit, CNRS UMR 5553, Université Joseph Fourier, B.P. 53, F-38041 Grenoble, Cedex 9, France.
| | | | | | | | | |
Collapse
|
41
|
Cannon Albright LA, Camp NJ, Farnham JM, MacDonald J, Abtin K, Rowe KG. A genealogical assessment of heritable predisposition to aneurysms. J Neurosurg 2003; 99:637-43. [PMID: 14567597 DOI: 10.3171/jns.2003.99.4.0637] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECT This study was conducted to investigate the familial and genetic contribution to intracranial, abdominal aortic, and all other types of aneurysms, and to define familial relationships among patients who present with the different aneurysm types. METHODS The authors used a unique Utah resource to perform population-based analysis of the familial nature of aneurysms. The Utah Population Data Base is a genealogy of the Utah population dating back eight generations, which is combined with death certificate data for the state of Utah dating back to 1904. Taking into account the genetic relationships among all aneurysm cases derived from this resource, the authors used a previously published method to estimate the familiality of different aneurysm types. Using internal, birth-cohort-specific rates of disease calculated from the database, they estimated relative risks by comparing observed to expected rates of aneurysm incidence in defined sets of relatives of probands. CONCLUSIONS Each of the three aneurysm types investigated showed significant evidence for a genetic component. Relatives of patients with intracranial aneurysms do not appear to be at increased risk for abdominal or other lesions, but relatives of patients with abdominal aortic aneurysms appear to be at increased risk for other types of these lesions.
Collapse
Affiliation(s)
- Lisa A Cannon Albright
- Department of Medical Informatics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
| | | | | | | | | | | |
Collapse
|
42
|
Björnsson Á, Gudmundsson G, Gudfinnsson E, Hrafnsdóttir M, Benedikz J, Skúladóttir S, Kristjánsson K, Frigge ML, Kong A, Stefánsson K, Gulcher JR. Localization of a gene for migraine without aura to chromosome 4q21. Am J Hum Genet 2003; 73:986-93. [PMID: 14513409 PMCID: PMC1180504 DOI: 10.1086/378417] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2003] [Accepted: 07/10/2003] [Indexed: 11/03/2022] Open
Abstract
Migraine is a common form of headache and has a significant genetic component. Here, we report linkage results from a study in Iceland of migraine without aura (MO). The study group comprised patients with migraine recruited by neurologists and from the registry of the Icelandic Migraine Society, as well as through the use of a questionnaire sent to a random sample of 20,000 Icelanders. Migraine diagnoses were made and confirmed using diagnostic criteria established by the International Headache Society. A genome-wide scan with multipoint allele-sharing methods was performed on 289 patients suffering from MO. Linkage was observed to a locus on chromosome 4q21 (LOD=2.05; P=.001). The locus reported here overlaps a locus (MGR1) reported elsewhere for patients with migraine with aura (MA) in the Finnish population. This replication of the MGR1 locus in families with MO indicates that the gene we have mapped may contribute to both MA and MO. Further analysis indicates that the linkage evidence improves for affected females and, especially, with a slightly relaxed definition of MO (LOD=4.08; P=7.2 x 10(-6)).
Collapse
Affiliation(s)
- Ásgeir Björnsson
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - Grétar Gudmundsson
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - Einar Gudfinnsson
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - María Hrafnsdóttir
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - John Benedikz
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - Svanhildur Skúladóttir
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - Kristleifur Kristjánsson
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - Michael L. Frigge
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - Augustine Kong
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - Kári Stefánsson
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| | - Jeffrey R. Gulcher
- deCODE Genetics and Landspitalinn-University Hospital, Reykjavik; and Haukeland-University Hospital, Bergen, Norway
| |
Collapse
|
43
|
Helgason A, Nicholson G, Stefánsson K, Donnelly P. A reassessment of genetic diversity in Icelanders: strong evidence from multiple loci for relative homogeneity caused by genetic drift. Ann Hum Genet 2003; 67:281-97. [PMID: 12914564 DOI: 10.1046/j.1469-1809.2003.00046.x] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
There has been some controversy in the literature concerning whether Icelanders are genetically homogenous or heterogeneous relative to other European populations. We reassess this question in the light of large data sets spanning 83 autosomal SNP loci, 14 serogenetic loci, 6622 Y-chromosomes and 3214 sequences from mtDNA hypervariable segments 1 and 2 (HVS1 and HVS2). Our results strongly support the hypothesis that genetic drift, with a consequent loss of variation, has had a greater impact on Icelanders than most other Europeans. We also analyse 7245 HVS1 sequences from 25 European populations. In line with other studies, we observe a deficit of rare HVS1 haplotypes and an excess of intermediate frequency haplotypes in Icelanders compared to most European populations, with some measures of genetic diversity indicating relative heterogeneity and others indicating relative homogeneity of Icelanders. Simulations indicate that genetic drift, and not admixture (as proposed by Arnason, 2003) is the most likely cause of the atypical Icelandic HVS1 frequency spectrum. These simulations reveal that gene diversity (heterozygosity) and mean pairwise differences are largely insensitive to events in recent population history, while statistics based on the number of haplotypes or segregating sites are much more sensitive. Overall, our analyses strongly indicate that the Icelandic gene pool is less heterogeneous than those of most other European populations.
Collapse
Affiliation(s)
- A Helgason
- deCODE Genetics, 101 Reykjavik, Iceland.
| | | | | | | |
Collapse
|
44
|
Stefánsson SE, Jónsson H, Ingvarsson T, Manolescu I, Jónsson HH, Ólafsdóttir G, Pálsdóttir E, Stefánsdóttir G, Sveinbjörnsdóttir G, Frigge ML, Kong A, Gulcher JR, Stefánsson K. Genomewide scan for hand osteoarthritis: a novel mutation in matrilin-3. Am J Hum Genet 2003; 72:1448-59. [PMID: 12736871 PMCID: PMC1180305 DOI: 10.1086/375556] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2002] [Accepted: 03/18/2003] [Indexed: 11/03/2022] Open
Abstract
Osteoarthritis (OA) is the most common human joint disease, characterized by loss and/or remodeling of joint synovium, cartilage, and bone. Here, we describe a genomewide linkage analysis of patients with idiopathic hand OA who were carefully phenotyped for involvement of either or both the distal interphalangeal (DIP) joints and the first carpometacarpal (CMC1) joints. The best linkage peaks were on chromosomes 4q and 3p and on the short arm of chromosome 2. Genomewide significance was reached for a locus on chromosome 2 for patients with affected CMC1 joints (LOD = 4.97); this locus was also significant for patients with OA in both CMC1 and DIP joints (LOD = 4.44). The peak LOD score at this locus coincides with a gene, MATN3, encoding the noncollagenous cartilage extracellular matrix protein, matrilin-3. Subsequent screening of the genomic sequence revealed a missense mutation, of a conserved amino acid codon, changing threonine to methionine in the epidermal growth factor-like domain in matrilin-3. The missense mutation cosegregates with hand OA in several families. The mutation frequency is slightly more than 2% in patients with hand OA in the Icelandic population and has a relative risk of 2.1.
Collapse
MESH Headings
- Amino Acid Sequence
- Chromosomes, Human, Pair 2
- Chromosomes, Human, Pair 3
- Chromosomes, Human, Pair 4
- Cohort Studies
- Extracellular Matrix Proteins/genetics
- Extracellular Matrix Proteins/metabolism
- Finger Joint
- Gene Frequency
- Genetic Linkage
- Genetic Markers
- Genetic Testing/methods
- Genome, Human
- Hand
- Haplotypes
- Humans
- Matrilin Proteins
- Molecular Sequence Data
- Mutation, Missense
- Osteoarthritis/diagnosis
- Osteoarthritis/genetics
- Pedigree
- Phenotype
- Polymorphism, Genetic
- Sequence Homology, Amino Acid
Collapse
Affiliation(s)
- Stefán Einar Stefánsson
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Helgi Jónsson
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Thorvaldur Ingvarsson
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Ileana Manolescu
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Hjörtur H. Jónsson
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Guðbjörg Ólafsdóttir
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Ebba Pálsdóttir
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Gerður Stefánsdóttir
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Guðfinna Sveinbjörnsdóttir
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Michael L. Frigge
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Augustine Kong
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Jeffrey R. Gulcher
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| | - Kári Stefánsson
- deCode Genetics, Landspítalinn University Hospital, and Genetic Research Service Center, Reykjavík; and Central Hospital, Akureyri, Iceland
| |
Collapse
|
45
|
Helgason A, Hrafnkelsson B, Gulcher JR, Ward R, Stefánsson K. A populationwide coalescent analysis of Icelandic matrilineal and patrilineal genealogies: evidence for a faster evolutionary rate of mtDNA lineages than Y chromosomes. Am J Hum Genet 2003; 72:1370-88. [PMID: 12721957 PMCID: PMC1180299 DOI: 10.1086/375453] [Citation(s) in RCA: 103] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2002] [Accepted: 03/11/2003] [Indexed: 11/04/2022] Open
Abstract
Historical inferences from genetic data increasingly depend on assumptions about the genealogical process that shapes the frequencies of alleles over time. Yet little is known about the structure of human genealogies over long periods of time and how they depart from expectations of standard demographic models, such as that attributed to Wright and Fisher. To obtain such information and to examine the recent evolutionary history of mtDNA and Y-chromosome haplotypes in the Icelandic gene pool, we traced the matrilineal and patrilineal ancestry of all 131,060 Icelanders born after 1972 back to two cohorts of ancestors, one born between 1848 and 1892 and the other between 1798 and 1742. This populationwide coalescent analysis of Icelandic genealogies revealed highly positively skewed distributions of descendants to ancestors, with the vast majority of potential ancestors contributing one or no descendants and a minority of ancestors contributing large numbers of descendants. The expansion and loss of matrilines and patrilines has caused considerable fluctuation in the frequencies of mtDNA and Y-chromosome haplotypes, despite a rapid population expansion in Iceland during the past 300 years. Contrary to a widespread assumption, the rate of evolution caused by this lineage-sorting process was markedly faster in matrilines (mtDNA) than in patrilines (Y chromosomes). The primary cause is a 10% shorter matrilineal generation interval. Variance in the number of offspring produced within each generation was not an important differentiating factor. We observed an intergenerational correlation in offspring number and in the length of generation intervals in the matrilineal and patrilineal genealogies, which was stronger in matrilines and thus contributes to their faster evolutionary rate. These findings may have implications for coalescent date estimates based on mtDNA and Y chromosomes.
Collapse
|
46
|
Thorgeirsson TE, Oskarsson H, Desnica N, Kostic JP, Stefansson JG, Kolbeinsson H, Lindal E, Gagunashvili N, Frigge ML, Kong A, Stefansson K, Gulcher JR. Anxiety with panic disorder linked to chromosome 9q in Iceland. Am J Hum Genet 2003; 72:1221-30. [PMID: 12679899 PMCID: PMC1180274 DOI: 10.1086/375141] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2002] [Accepted: 03/03/2003] [Indexed: 11/03/2022] Open
Abstract
The results of a genomewide scan for genes conferring susceptibility to anxiety disorders in the Icelandic population are described. The aim of the study was to locate genes that predispose to anxiety by utilizing the extensive genealogical records and the relative homogeneity of the Icelandic population. Participants were recruited in two stages: (1) Initial case-identification by a population screening for anxiety disorders, using the Stamm Screening Questionnaire, was followed by aggregation into extended families, with the help of our genealogy database; and (2) those who fulfilled the diagnostic and family aggregation criteria underwent a more detailed diagnostic workup based on the Composite International Diagnostic Interview. Screening for anxiety in close relatives also identified additional affected members within the families. After genotyping was performed with 976 microsatellite markers, affected-only linkage analysis was done, and allele-sharing LOD scores were calculated using the program Allegro. Linkage analysis of 25 extended families, in each of which at least one affected individual had panic disorder (PD), resulted in a LOD score of 4.18 at D9S271, on chromosome 9q31. The intermarker distance was 4.4 cM on average, whereas it was 1.5 cM in the linked region as additional markers were added to increase the information content. The linkage results may be relevant not only to PD but also to anxiety in general, since our linkage study included patients with other forms of anxiety.
Collapse
Affiliation(s)
| | - Högni Oskarsson
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | - Natasa Desnica
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | - Jelena Pop Kostic
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | - Jon G. Stefansson
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | - Halldor Kolbeinsson
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | - Eirikur Lindal
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | | | - Michael L. Frigge
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | - Augustine Kong
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | - Kari Stefansson
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| | - Jeffrey R. Gulcher
- deCode Genetics, Therapeia, and Landspitalinn-University Hospital, Reykjavík
| |
Collapse
|
47
|
Karason A, Gudjonsson JE, Upmanyu R, Antonsdottir AA, Hauksson VB, Runasdottir EH, Jonsson HH, Gudbjartsson DF, Frigge ML, Kong A, Stefansson K, Valdimarsson H, Gulcher JR. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 2003; 72:125-31. [PMID: 12474146 PMCID: PMC378616 DOI: 10.1086/345646] [Citation(s) in RCA: 138] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2002] [Accepted: 10/14/2002] [Indexed: 11/03/2022] Open
Abstract
Several genetic loci have been reported for psoriasis, but none has been specifically linked to psoriatic arthritis (PsA), a condition that affects >10% of patients with psoriasis. A genetic component for PsA is suggested by segregation within families and high concordance among identical twins. We performed a linkage scan to map genes contributing to PsA. We identified 178 patients with PsA out of 906 patients who were included in our genetic study of psoriasis. Using a comprehensive genealogy database, we were able to connect 100 of these into 39 families. We genotyped the patients using a framework marker set of 1,000 microsatellite markers, with an average density of 3 cM, and performed multipoint, affected-only, allele-sharing linkage analysis using the Allegro program. On the basis of the initial results, we genotyped more markers for the most prominent loci. A linkage with a LOD score of 2.17 was observed on chromosome 16q. The linkage analysis, conditioned on paternal transmission to affected individuals, gave a LOD score of 4.19, whereas a LOD score of only 1.03 was observed when conditioned for maternal transmission. A suggestive locus on chromosome 16q has previously been implicated in psoriasis. Our data indicate that a gene at this locus may be involved in paternal transmission of PsA.
Collapse
Affiliation(s)
- Ari Karason
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Johann E. Gudjonsson
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Ruchi Upmanyu
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Arna A. Antonsdottir
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Valdimar B. Hauksson
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - E. Hjaltey Runasdottir
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Hjortur H. Jonsson
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Daniel F. Gudbjartsson
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Michael L. Frigge
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Augustine Kong
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Kari Stefansson
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Helgi Valdimarsson
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| | - Jeffrey R. Gulcher
- deCODE Genetics and Department of Immunology, University National Hospital, Hringbraut, Reykjavik
| |
Collapse
|
48
|
Abstract
Recently statements have been made about a special 'genetic homogeneity' of the Icelanders that are at variance with earlier work on blood groups and allozymes. To validate these claims an extensive reanalysis was undertaken of mtDNA variation by examining primary data from original sources on 26 European populations. The results show that Icelanders are among the most genetically heterogeneous Europeans by the mean number of nucleotide differences as well as by estimates of theta parameters of the neutral theory. The distribution of pairwise differences in general has the same shape as European populations and shows no evidence of bottlenecks of numbers in Iceland. The allelic frequency distribution of Iceland is relatively even with a large number of haplotypes at polymorphic frequencies contrasting with other countries. This is a signature of admixture during the founding or history of Iceland. Assumptions of models used to simulate number of haplotypes at sampling saturation for comparing populations are violated to different degrees by various countries. Anomalies identified in data in previous reports on Icelandic mtDNA variation appear to be due to errors in publicly accessible databases. This study demonstrates the importance of basing analyses on primary data so that errors are not propagated. Claims about special genetic homogeneity of Icelanders are not supported by evidence.
Collapse
Affiliation(s)
- E Arnason
- Institute of Biology, University of Iceland, Grensásvegur 12, Reykjavík, Iceland.
| |
Collapse
|
49
|
Hakonarson H, Bjornsdottir US, Halapi E, Palsson S, Adalsteinsdottir E, Gislason D, Finnbogason G, Gislason T, Kristjansson K, Arnason T, Birkisson I, Frigge ML, Kong A, Gulcher JR, Stefansson K. A major susceptibility gene for asthma maps to chromosome 14q24. Am J Hum Genet 2002; 71:483-91. [PMID: 12119603 PMCID: PMC379187 DOI: 10.1086/342205] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2002] [Accepted: 06/03/2002] [Indexed: 11/03/2022] Open
Abstract
Asthma is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. Numerous loci and candidate genes have been reported to show linkage and association to asthma and atopy. Although some studies reporting these observations are compelling, no gene has been mapped that confers a sufficiently high risk of asthma to meet the stringent criteria for genomewide significance. Using 175 extended Icelandic families that included 596 patients with asthma, we performed a genomewide scan with 976 microsatellite markers. The families were identified by cross-matching a list of patients with asthma from the Department of Allergy/Pulmonary Medicine of the National University Hospital of Iceland with a genealogy database of the entire Icelandic nation. We detected linkage of asthma to chromosome 14q24, with an allele-sharing LOD score of 2.66. After we increased the marker density within the locus to an average of one microsatellite every 0.2 cM, the LOD score rose to 4.00. We designate this locus "asthma locus one" (AS1). Taken together, these results provide evidence of a novel susceptibility gene for asthma on chromosome 14q24.
Collapse
Affiliation(s)
- Hakon Hakonarson
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Unnur S. Bjornsdottir
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Eva Halapi
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Snaebjorn Palsson
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Elva Adalsteinsdottir
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - David Gislason
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Gudmundur Finnbogason
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Thorarinn Gislason
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Kristleifur Kristjansson
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Thor Arnason
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Illugi Birkisson
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Michael L. Frigge
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Augustine Kong
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Jeffrey R. Gulcher
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| | - Kari Stefansson
- deCODE Genetics, Inc., and Department of Allergy/Pulmonary Medicine, National University Hospital, Reykjavik, Iceland
| |
Collapse
|
50
|
Gudbjartsson T, Jónasdóttir TJ, Thoroddsen A, Einarsson GV, Jónsdóttir GM, Kristjánsson K, Hardarson S, Magnússon K, Gulcher J, Stefánsson K, Amundadóttir LT. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 2002; 100:476-9. [PMID: 12115533 DOI: 10.1002/ijc.10513] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The etiology of RCC is incompletely understood and the inherited genetic contribution uncertain. Although there are rare mendelian forms of RCC stemming from inherited mutations, most cases are thought to be sporadic. We sought to determine the extent of familial aggregation among Icelandic RCC patients in general. Medical and pathologic records for all patients diagnosed with RCC in Iceland between 1955 and 1999 were reviewed. This included a total of 1,078 RCC cases, 660 males and 418 females. With the use of an extensive computerized database containing genealogic information on 630,000 people in Iceland during the past 11 centuries, several analyses were conducted to determine whether the patients were more related to each other than members drawn at random from the population. Patients with RCC were significantly more related to each other than were subjects in matched groups of controls. This relatedness extended beyond the nuclear family. RRs were significantly greater than 1.0 for siblings, parents and cousins of probands. RRs were 2-3 for first-degree relatives and 1.6 for third-degree relatives. The risk of RCC is significantly higher for members of the extended family of an affected individual, as well as the nuclear family. Our results indicate that germline mutations are significantly involved in what has been defined as sporadic RCC.
Collapse
|